392
Participants
Start Date
November 28, 2017
Primary Completion Date
February 28, 2021
Study Completion Date
February 25, 2022
Saxenda
standard care plus targeted use of Liraglutide (LIRA) 3mg when pre-specified stopping rules for the medication apply. Liraglutide (Saxenda) 6 mg/mL solution for injection in pre-filled pen, administered by subcutaneous injection. Dose escalation to 3.0 mg daily (or maximum tolerated dose)
Specialist Obesity Management Services
Specialist Obesity Management Services standard of care
St Vincent's University Hospital, Dublin
NHS Greater Glasgow and Clyde West Glasgow Ambulatory Care Hospital, Glasgow
University Hospitals of Leicester NHS Trust, Leicester General Hospital, Leicester
University Hospital Aintree, Liverpool
Guy's and St Thomas' NHS Foundation Trust, London
Collaborators (1)
Novo Nordisk A/S
INDUSTRY
University of Leicester
OTHER